Quantcast

Latest radiation therapy Stories

2014-03-20 12:28:30

The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions MOUNTAIN VIEW, Calif., March 20, 2014 /PRNewswire/ -- Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation...

2014-03-19 23:32:06

Rumors Finally Put to Rest, Ahmad ‘Real’ Givens of ‘Real Chance of Love’ is a Survivor (PRWEB) March 19, 2014 This week marks the one year anniversary of the former ‘Real Chance of Love’ star, Ahmad ‘Real’ Givens devastating diagnosis of stage 4 colon cancer. He and his brothers (Kamal ‘Chance’ Givens and Micah Givens) who are also his group members, known as The Stallionaires are celebrating by releasing their new single and video titled ‘I’m Bad’, a song that...

2014-03-18 12:31:04

Central Texas CyberKnife center marks nine years of cancer care AUSTIN, Texas, March 18, 2014 /PRNewswire/ -- Austin CyberKnife marks an important milestone in cancer care with the treatment of its 1,000th patient. University Medical Center Brackenridge, launched the CyberKnife program in 2005 and focused primarily on the treatment of brain tumors. Austin CyberKnife has since expanded the clinical applications of CyberKnife to treat other areas of the body, such as the lungs,...

2014-03-18 08:33:40

CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to (1) identify the recommended Phase 2 dose of CRLX101 in combination with Xeloda(®) (capecitabine) and radiation (chemoradiotherapy) and (2) detect signals, if any, of increased efficacy over standard neoadjuvant chemoradiotherapy for rectal cancer. The trial is...

2014-03-13 20:24:05

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/w548d6/us_proton_therapy) have announced the addition of the "Concise Analysis of the US Proton Therapy Market" [http://www.researchandmarkets.com/research/w548d6/us_proton_therapy ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) According to most Oncologists, about 60% of all cancer patients undergo some sort of...

2014-03-13 16:28:44

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/8rl45x/us_proton_therapy) have announced the addition of the "US Proton Therapy Outlook 2017" [http://www.researchandmarkets.com/research/8rl45x/us_proton_therapy ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Physicians, in the face of an alarmingly rising incidences of cancer and limited treatment options are being...

2014-03-13 12:28:27

CRAWLEY, England, March 13, 2014 /PRNewswire/ -- A little over a year after Elekta launched its Versa HD(TM) radiation therapy system, this groundbreaking linear accelerator is routinely being used in the delivery of stereotactic body radiotherapy (SBRT) and radiosurgery (SRS) programs worldwide, often using volumetric modulated arc therapy (VMAT). The company reports that many Versa HD systems operating clinically are actively engaged in SBRT and/or SRS programs. Elekta designed...

2014-03-12 23:30:14

DEXshield™, a new, innovative product from DEXIS, enables DEXIS® Platinum Sensor owners to reduce radiation exposure to their patients. Hatfield, PA (PRWEB) March 12, 2014 DEXIS is excited to announce the introduction of DEXshield, a unique dental X-ray position indicating device and a patented patient protective shield. When used in conjunction with the DEXIS Platinum Sensor, this exciting new device not only reduces radiation to the patient, it also aids in proper positioning for...

2014-03-12 08:30:27

PALO ALTO, Calif., March 12, 2014 /PRNewswire/ -- Varian Medical Systems, Inc., (NYSE: VAR) today announced it has signed an agreement with Velocity Medical Solutions, LLC to acquire certain assets of Velocity, a privately-held Atlanta-based developer of specialized software for cancer clinics. The acquisition includes software designed to access and aggregate unstructured treatment and imaging data from diverse systems to show a comprehensive view of a patient's diagnostic imaging...

2014-03-11 23:22:25

UVA study’s surprising finding: Direct treatment of tumor prolongs survival. Charlottesville, VA (PRWEB) March 11, 2014 Contrary to the standard approach to treating metastatic prostate cancer, direct treatment of the primary tumor appears to prolong survival significantly, a new study suggests. The surprising findings have prompted the researchers to launch clinical trials that could upend the accepted treatment of the disease. Prostate Cancer Survival Rate Prostate cancer is the most...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related